Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

As the cancer day care centre at AIIMS, Delhi, spills over, families hope decentralised treatment will cut costs, minimise ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival ...

Real-world safety of trastuzumab deruxtecan with gastric cancer: All-patient post-marketing surveillance study in Japan. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

Although this is true for many people with iron deficiency, it can be much more complicated. When determining which iron therapy—oral or intravenous (IV)—is right for you, it is important to consider ...

The patients were randomly assigned to receive adjuvant treatment with T-DM1 at 3.6 mg/kg (n=743) or trastuzumab at 6 mg/kg (n=743) every 3 weeks for 14 cycles. Baseline characteristics were ...

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs ...

The other 743 women (median age, 49 years; range, 23-80; 71.5% white) received trastuzumab 6 mg/kg via IV every 3 weeks for 14 cycles. Invasive DFS served as the primary endpoint. OS served as a ...

every three weeks or IV trastuzumab monotherapy at a dose 6 mg per kilogram every three weeks for 14 cycles. Randomization was arranged as per clinical stage at presentation, specifically inoperable ...

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...